Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024875 | 0.70 | ADAM17 (0.43) | POLBMAPK1SMN1; SMN2PKMLMNA | |
| SCHEMBL31043063 | 0.65 | CES1 (0.43) | MAPK1CES1LMNAL3MBTL1 | |
| SCHEMBL1931269 | 0.64 | HTT (0.71) | POLBSMN1; SMN2PKMLMNAL3MBTL1 | |
| SCHEMBL27889659 | 0.64 | HTT (0.47) | POLBSMN1; SMN2PKMLMNAFFAR1 | |
| SCHEMBL10824817 | 0.64 | ALDH1A1 (0.51) | POLBCPA1LMNAFFAR1HTT | |
| SCHEMBL9099120 | 0.64 | HTT (0.71) | POLBSMN1; SMN2PKMLMNAL3MBTL1 | |
| SCHEMBL8558691 | 0.64 | GRM2 (0.49) | PKMHTTKIF11 | |
| Methylphenylsulfide SCHEMBL9409875 | 0.62 | DPP4 (0.41) | POLBMAPK1CPA1CES1SMN1; SMN2 | |
| SCHEMBL5052962 | 0.62 | FOLH1 (0.71) | HTTFOLH1ALOX5PPARGPPARA | |
| Diphenylsulfane SCHEMBL6380924 | 0.62 | HPGD (0.52) | CPA1CES1LMNAL3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564995-B2 | Peptide-nanoparticle conjugates | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210187120-A1 | PEPTIDE-NANOPARTICLE CONJUGATES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2021-06-24 | — | — | US | disclosed |
| US-6964948-B2 | Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing protein | XOMA TECHNOLOGY LTD. (BM) | 2005-11-15 | — | — | US | disclosed |
| US-6664231-B1 | Based on Domain III (amino acids 142-169) of bactericidal/ permeability-increasing protein; candida, aspergillus, cryptococcus | XOMA CORPORATION | 2003-12-16 | — | — | US | disclosed |
| US-20030144195-A1 | Therapeutic peptide-based constructs | LITTLE ROGER G (US) | 2003-07-31 | — | — | US | disclosed |
| US-6515104-B1 | 8-15 amino acid moieties having heparin neutralization and binding and inhibiting endothelial cell proliferation and/or angiogenesis; diagnotic applications | XOMA TECHNOLOGY LTD. (BM) | 2003-02-04 | — | — | US | disclosed |
| US-6423825-B1 | OCTA-, NONA-, DECA- OR POLYPEPTIDE; HEPARIN BINDING AND NEUTRALIZATION; ANTIPROLIFERATIVE AGENTS OF ENDOTHELIAL CELLS; ANGIOGENESIS INHIBITORS | XOMA TECHNOLOGY LTD. (BM) | 2002-07-23 | — | — | US | disclosed |
| US-20020077298-A1 | Anti-fungal peptides | XOMA CORPORATION | 2002-06-20 | — | — | US | disclosed |
| US-6355616-B1 | FUNGICIDE OLIGOPEOTIDES | XOMA (US) TECHNOLOGY LTD. | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144195-A1 | Therapeutic peptide-based constructs | LNPEP, SPPL2B, ENPEP | POLB 703/4885MAPK1 3703/4885CPA1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.